menu

Transforming the Standard of Care in CML by Mastering Response-Guided Treatment

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Expert Answers to Common Questions on Response Matters: Transforming the Standard of Care in CML by Mastering Response-Guided Treatment

0.25 credits
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Chronic myeloid leukemia is a myeloproliferative neoplasm characterized by disordered growth of myeloid cells. The hallmark of chronic myeloid leukemia (CML) is an acquired reciprocal translocation between the long arms of chromosomes 9 and 22. This translocation results in the BCR-ABL1 fusion protein, with constitutively active tyrosine kinase activity, and is the underlying driver of CML. BCR-ABL1 testing is widely used to confirm the clinical diagnosis of CML and to assess response to TKI therapy. The development of BCR-ABL1 tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of CML, dramatically improving patient outcomes. Although most CML patients experience excellent clinical outcomes, some CML patients (20-30%) exhibit an acquired resistance to treatment during the disease course, often requiring second- or third-line therapy. Novel TKIs designed to overcome TKI resistance have shown efficacy in early clinical trials and are offering promise to CML patients who do not respond to any of the multiple therapeutic options currently available. 

    AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions and answers provide incredible insight and address genetic testing, risk stratification, disease stages, and optimal treatment for patients with CML. This includes a focus on the clinical significance of BCR-ABL testing, cytogenic remission and deep molecular responses, mechanisms behind TKI resistance, stratification, updated guideline recommendations, emerging treatment strategies, and evidence-based strategies for optimal clinical decision-making 

  • Disclosure of Relevant Financial Relationships

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, peer reviewers, and other individuals who are in a position to control the content of this activity to disclose allpersonalfinancialrelationships they mayhave in the past 24 months with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are identified and mitigated prior to initiation of the planning phase for an activity.  

    AXIS has mitigated and disclosed to learners all relevant financial relationships disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity. 

    The faculty, Michael J. Mauro, MD, reported a financial interest/relationship or affiliation in the form of Grants/Research Support: Novartis, SPARC/Sun Pharma, Bristol Myers Squibb, Takeda, Enliven (All funding to the institution [Memorial Sloan Kettering Cancer Center]). Consulting Fees:Novartis Oncology, Takeda, Bristol Myers Squibb, AbbVie, Terns. 

    The directors, planners, managers, peer reviewers, and relevant staff reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:  Linda Gracie-King, MS; Elizabeth Lurwick, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; Melissa Duffy, PA-C; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months. 

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to: 

    • Formulate strategies to individualize molecular testing in CML patients to drive appropriate treatment selection based on guideline recommendations, risk stratification, and endpoints of treatment response. 

    • Apply updated guidelines, clinical trial data, and real-world evidence of 2nd and 3rd generation TKIs and BCR-ABL inhibitors to develop personalized treatment regimens for CML patients. 

    • Propose effective mitigation and management approaches for potential AEs and drug resistance in CML patients. 

  • Target Audience

    This educational activity is designed for hematologists, hematology oncologists, pathologists/lab professionals, oncology nurses, nurse practitioners, pharmacists, and physician assistants who are part of the interprofessional team responsible for the therapeutic management of patients with chronic myeloid leukemia (CML).  

  • Accreditation and Credit Designation Statements

     Accreditation Statement
    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 
    This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians 
    AXIS Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Credit Designation for Physician Assistants 

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits.  Approval is valid until 02/12/2025. PAs should only claim credit commensurate with the extent of their participation. 

    Credit Designation for Pharmacists 
    This knowledge-based activity is approved for 0.25 contact hour of continuing pharmacy education JA4008106-0000-24-004-H01-P 

    Credit Designation for Nursing 
    AXIS Medical Education designates this continuing nursing education activity for 0.25 contact hour. 

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity. 

    Credit Designation for Laboratory Professionals 
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 0.25 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program. 

  • Provider(s)/Educational Partner(s)

    Provided by

  • Commercial Support

    This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation. 

  • Disclaimer

    Disclosure of Unlabeled Use 
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information. 

    Disclaimer 
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Chronic myeloid leukemia is a myeloproliferative neoplasm characterized by disordered growth of myeloid cells. The hallmark of chronic myeloid leukemia (CML) is an acquired reciprocal translocation between the long arms of chromosomes 9 and 22. This translocation results in the BCR-ABL1 fusion protein, with constitutively active tyrosine kinase activity, and is the underlying driver of CML. BCR-ABL1 testing is widely used to confirm the clinical diagnosis of CML and to assess response to TKI therapy. The development of BCR-ABL1 tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of CML, dramatically improving patient outcomes. Although most CML patients experience excellent clinical outcomes, some CML patients (20-30%) exhibit an acquired resistance to treatment during the disease course, often requiring second- or third-line therapy. Novel TKIs designed to overcome TKI resistance have shown efficacy in early clinical trials and are offering promise to CML patients who do not respond to any of the multiple therapeutic options currently available. 

    AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions and answers provide incredible insight and address genetic testing, risk stratification, disease stages, and optimal treatment for patients with CML. This includes a focus on the clinical significance of BCR-ABL testing, cytogenic remission and deep molecular responses, mechanisms behind TKI resistance, stratification, updated guideline recommendations, emerging treatment strategies, and evidence-based strategies for optimal clinical decision-making 

  • Disclosure of Relevant Financial Relationships

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, peer reviewers, and other individuals who are in a position to control the content of this activity to disclose allpersonalfinancialrelationships they mayhave in the past 24 months with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are identified and mitigated prior to initiation of the planning phase for an activity.  

    AXIS has mitigated and disclosed to learners all relevant financial relationships disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity. 

    The faculty, Michael J. Mauro, MD, reported a financial interest/relationship or affiliation in the form of Grants/Research Support: Novartis, SPARC/Sun Pharma, Bristol Myers Squibb, Takeda, Enliven (All funding to the institution [Memorial Sloan Kettering Cancer Center]). Consulting Fees:Novartis Oncology, Takeda, Bristol Myers Squibb, AbbVie, Terns. 

    The directors, planners, managers, peer reviewers, and relevant staff reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:  Linda Gracie-King, MS; Elizabeth Lurwick, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; Melissa Duffy, PA-C; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months. 

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to: 

    • Formulate strategies to individualize molecular testing in CML patients to drive appropriate treatment selection based on guideline recommendations, risk stratification, and endpoints of treatment response. 

    • Apply updated guidelines, clinical trial data, and real-world evidence of 2nd and 3rd generation TKIs and BCR-ABL inhibitors to develop personalized treatment regimens for CML patients. 

    • Propose effective mitigation and management approaches for potential AEs and drug resistance in CML patients. 

  • Target Audience

    This educational activity is designed for hematologists, hematology oncologists, pathologists/lab professionals, oncology nurses, nurse practitioners, pharmacists, and physician assistants who are part of the interprofessional team responsible for the therapeutic management of patients with chronic myeloid leukemia (CML).  

  • Accreditation and Credit Designation Statements

     Accreditation Statement
    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 
    This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians 
    AXIS Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Credit Designation for Physician Assistants 

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits.  Approval is valid until 02/12/2025. PAs should only claim credit commensurate with the extent of their participation. 

    Credit Designation for Pharmacists 
    This knowledge-based activity is approved for 0.25 contact hour of continuing pharmacy education JA4008106-0000-24-004-H01-P 

    Credit Designation for Nursing 
    AXIS Medical Education designates this continuing nursing education activity for 0.25 contact hour. 

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity. 

    Credit Designation for Laboratory Professionals 
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 0.25 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program. 

  • Provider(s)/Educational Partner(s)

    Provided by

  • Commercial Support

    This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation. 

  • Disclaimer

    Disclosure of Unlabeled Use 
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information. 

    Disclaimer 
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule19 Apr 2024